Literature DB >> 22685015

Hepatitis C virus NS3/4A protease blocks IL-28 production.

Qiang Ding1, Bing Huang, Jie Lu, Yong-Jun Liu, Jin Zhong.   

Abstract

Type I interferons (IFNs), including IFN-α, -β, and -ω, play a critical role in innate immune responses against viral infection. IFN-λ, including IL-29, IL-28A, and IL-28B, recently identified as a new subfamily of IFN named type III IFN, has also been demonstrated to suppress virus replication in vitro and in vivo. However, the molecular mechanisms that regulate the induction of type III IFNs during viral infection remain elusive. Here, we demonstrate that IL-28 (IFN-λ 2/3) IFN production, similar to type I IFN, represents a primary and direct host response to HCV genomic RNA transfection. IL-28 (IFN-λ2/3) induction by HCV genomic RNA was dependent upon the activation of NF-κB and IRF3. We identified a minimal IL-28 promoter region consisting of putative NF-κB and IRF3-binding sites. Furthermore, we showed that HCV infection can inhibit HCV genomic RNA-induced IL-28 expression, and that the viral NS3/4A protease activity was responsible for this inhibitory effect. Our results present important evidence for the control of type III IFN response by HCV, and shed more light on the molecular mechanisms underlying the persistence of HCV infection.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22685015     DOI: 10.1002/eji.201242388

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  19 in total

1.  Identification of Cholesterol 25-Hydroxylase as a Novel Host Restriction Factor and a Part of the Primary Innate Immune Responses against Hepatitis C Virus Infection.

Authors:  Yu Xiang; Jing-Jie Tang; Wanyin Tao; Xuezhi Cao; Bao-Liang Song; Jin Zhong
Journal:  J Virol       Date:  2015-04-22       Impact factor: 5.103

Review 2.  MAVS Coordination of Antiviral Innate Immunity.

Authors:  Christine Vazquez; Stacy M Horner
Journal:  J Virol       Date:  2015-05-06       Impact factor: 5.103

3.  A new transcription factor ATG10S activates IFNL2 transcription by binding at an IRF1 site in HepG2 cells.

Authors:  Miao-Qing Zhang; Qiong Zhao; Jing-Pu Zhang
Journal:  Autophagy       Date:  2020-01-29       Impact factor: 16.016

4.  Transcriptional regulation of IFN-λ genes in hepatitis C virus-infected hepatocytes via IRF-3·IRF-7·NF-κB complex.

Authors:  Hai-Chon Lee; Sowmya Narayanan; Sung-Jae Park; Seung-Yong Seong; Young S Hahn
Journal:  J Biol Chem       Date:  2014-01-02       Impact factor: 5.157

5.  Novel Stable Ebola Virus Minigenome Replicon Reveals Remarkable Stability of the Viral Genome.

Authors:  Wanyin Tao; Tianyu Gan; Mingzhe Guo; Yongfen Xu; Jin Zhong
Journal:  J Virol       Date:  2017-10-27       Impact factor: 5.103

Review 6.  The Role of Nucleic Acid Sensing in Controlling Microbial and Autoimmune Disorders.

Authors:  Keesha M Matz; R Marena Guzman; Alan G Goodman
Journal:  Int Rev Cell Mol Biol       Date:  2018-09-25       Impact factor: 6.813

Review 7.  Genetic variants at the IFNL3 locus and their association with hepatitis C virus infections reveal novel insights into host-virus interactions.

Authors:  Sreedhar Chinnaswamy
Journal:  J Interferon Cytokine Res       Date:  2014-02-20       Impact factor: 2.607

8.  Establishment of a novel triple-transgenic mouse: conditionally and liver-specifically expressing hepatitis C virus NS3/4A protease.

Authors:  H Y Lan; Y Zhao; J Yang; M N Sun; Y F Lei; M Yao; X J Huang; J M Zhang; Z K Xu; X Lü; W Yin
Journal:  Mol Biol Rep       Date:  2014-09-09       Impact factor: 2.316

Review 9.  Immunopathogenesis of Hepatitis C Virus Infection.

Authors:  David E Kaplan
Journal:  Gastroenterol Clin North Am       Date:  2015-08-13       Impact factor: 3.806

10.  IFN-λ exerts opposing effects on T cell responses depending on the chronicity of the virus infection.

Authors:  Ichiro Misumi; Jason K Whitmire
Journal:  J Immunol       Date:  2014-03-19       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.